Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
About this trial
This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.
Eligibility criteria
Qualifiers
Participants underwent radical resection of hepatocellular carcinoma 4 weeks before randomization
High Risk of recurrence as assessed by tumor characteristics
Without any anti-tumor therapy before surgery, except preoperative TACE therapy, traditional Chinese medicine therapy and interferon therapy
Child-Pugh Class A statu
Disqualifiers
Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
Evidence of residual or a history of spontaneous tumor rupture
Recurrent HCC
Prior received Liver transplantation
Trial design
Treatments tested in this trial
- Donafenib
Treatment groups
204 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov